Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.